Uncategorized

Lilly, Ascidian link up in RNA exon editing pact

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

Published

1 week ago

on

June 3, 2026

By

Temp User

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Endpoints News3 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season

Exit mobile version